{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":3,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":47,"n_cols":5,"rows_kept":47,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[10,2,10,3],[11,2,11,3],[12,2,12,3],[15,2,15,3],[15,4,15,5],[16,2,16,3],[16,4,16,5],[17,2,17,3],[17,4,17,5],[18,2,18,3],[19,2,19,3],[20,2,20,3],[21,2,21,3],[22,2,22,3],[26,2,26,3],[26,4,26,5],[27,2,27,3],[27,4,27,5],[28,2,28,3],[28,4,28,5],[29,2,29,3],[31,2,31,3],[33,2,33,3],[34,2,34,3],[35,2,35,3],[37,2,37,3],[38,2,38,3],[41,2,41,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNISA990003677800203316"]
[null,null,"Autore",null,"CORTE DEI CONTI EUROPEA"]
[null,null,"Titolo",null,"I programmi \"Latte alle scuole\" e \"Frutta nelle scuole\" sono efficaci? / Corte dei conti europea"]
[null,null,"Pubbl/distr/stampa",null,"Lussemburgo : Ufficio delle pubblicazioni dell'Unione europea, 2011"]
[null,null,"ISBN",null,"978-92-9237-295-8"]
[null,null,"Descrizione fisica",null,"64 p. : ill. ; 30 cm"]
[null,null,"Collana",null,"Relazione speciale ; 10"]
[null,null,"Disciplina",null,"338.476132083094"]
[null,null,"Soggetti",null,"Latte [e] Latticini - Scuole dell'obbligo - Paesi dell'Unione europea"]
[{"$nulls":4},"Frutta - Scuole dell'obbligo - Paesi dell'Unione europea"]
[null,null,"Collocazione",null,"CDE 07.05 (VI)"]
[null,null,"Lingua di pubblicazione",null,"Italiano"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Sommario/riassunto","L'UE sovvenziona da oltre 30 anni la cessione a prezzo ridotto di prodotti lattiero caseari alle scuole ed ha recentemente lanciato un secondo programma per la distribuzione di frutta. La Corte ha effettuato un audit congiunto dei due programmi onde verificarne l'efficacia. In questa relazione, la Corte constata l'efficacia molto limitata del programma \"latte alle scuole\", che soffre in particolare di un significativo effetto inerziale e di una scarsa dimensione pedagogica. Basandosi su certe buone pratiche osservate e sull’avvio promettente delle distribuzioni gratuite di frutta, la relazione mostra tuttavia che sono ipotizzabili delle soluzioni. [Abstract tratto dalla pubblicazione]"]
[null,"2.","Record Nr.",null,"UNISA996385347903316"]
[null,null,"Autore",null,"Coles William <1626-1662.>"]
[null,null,"Titolo",null,"Adam in Eden, or, Natures paradise [[electronic resource] ] : the history of plants, fruits, herbs and flowers with their several names ... the places where they grow, their descriptions and kinds, their times of flourishing and decreasing as also their several signatures, anatomical appropriations and particular physical vertues together with necessary observations on the seasons of planting and gathering of our English simples with directions how to preserve them in their compositions or otherwise : ... there is annexed a Latin and English table of the several names of simples, with another more particular table of the diseases and their cures ... / / by William Coles ."]
[null,null,"Pubbl/distr/stampa",null,"London, : Printed by J. Streater for Nathaniel Brooke ..., 1657"]
[null,null,"Descrizione fisica",null,"[20], 629, [22] p. : ill"]
[null,null,"Soggetti",null,"Botany, Medical"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Reproduction of original in British Library."]
[null,null,null,"Sommario/riassunto","eebo-0018"]
[null,"3.","Record Nr.",null,"UNINA9910544850603321"]
[null,null,"Autore",null,"Mallick Umair"]
[null,null,"Titolo",null,"Cardiovascular complications of COVID-19 : risk, pathogenesis and outcomes / / Umair Mallick"]
[null,null,"Pubbl/distr/stampa",null,"Cham, Switzerland : , : Springer, , [2022]"]
[{"$nulls":4},"©2022"]
[null,null,"ISBN",null,"9783030900656"]
[{"$nulls":4},"9783030900649"]
[null,null,"Descrizione fisica",null,"1 online resource (416 pages)"]
[null,null,"Disciplina",null,"614.592414"]
[null,null,"Soggetti",null,"COVID-19 (Disease)"]
[{"$nulls":4},"Cardiovascular system - Diseases"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Intro -- Contents -- 1 The Epidemiology of CoViD19 and Cardiovascular Diseases -- 1.1 Introduction -- 1.2 Epidemiology -- 1.2.1 Cardiovascular Disease or CoViD19, Which Comes First? -- 1.2.2 The Burden of Cardiovascular Risk Factors in CoViD19 -- 1.2.3 Role of the Pre-existing Cardiovascular Diseases in CoViD19 -- 1.2.4 Critical CoViD19 Complications and Pre-existing Cardiovascular Disease -- 1.2.5 Role of Cardiovascular Complications in CoViD19 Mortality -- 1.3 Discussion -- 1.4 Conclusion -- References -- 2 Virology of CoViD19 -- 2.1 Viral Characteristics -- 2.1.1 Origins of SARS CoV2 -- 2.1.2 Hosts -- 2.1.3 SARS CoV2 Structure -- 2.1.4 SARS CoV2 Affinity and Infectivity -- 2.1.5 SARS CoV2 Variability and Strains -- 2.2 Mechanism of Viral Entry in Cells -- 2.2.1 SARS CoV2 Viral Spike-ACE2 Signaling Mechanisms -- 2.2.2 SARS COV, Cell Entry, and Receptors -- 2.2.3 SARS CoV2 Similarities with SARS COV and MERS -- 2.2.4 SARS CoV2, Cell Entry and Receptors -- 2.3 Summary -- References -- 3 An Introduction to the Clinical and Diagnostic Features, and CoViD19 Complications -- 3.1 Introduction -- 3.2 Clinical Symptomatology -- 3.3 Sepsis and Complications of CoViD19 -- 3.4 Important Diagnostic Features -- 3.4.1 Viral Sampling -- 3.4.2 Biochemical and Hematological Features -- 3.4.3 Radiological Features -- 3.5 Summary -- References -- 4 The Pathological Features of CoViD19 Cardiovascular Complications -- 4.1 Introduction -- 4.2 Key Features of Cardiovascular Pathology -- 4.2.1 The Myocardial Injury in CoViD19 "]
[{"$nulls":4},"-- 4.2.2 Endomyocardial Biopsy and Myocarditis -- 4.2.3 Endomyocardial Biopsy and Myocarditis with Viral Localization -- 4.2.4 The Vascular Injury, Microvascular Cardiac Involvement, and Thromboembolic Features -- 4.2.5 Endothelial Cell Infection and Apoptosis -- 4.3 Summary -- References -- 5 Treatment Options in CoViD19 -- 5.1 Introduction."]
[{"$nulls":4},"5.2 Antiviral Agents in CoViD19 -- 5.2.1 Viral Cell Entry Inhibition and Viral Assembly Blockage -- 5.3 Amino Quinolones in CoViD19 -- 5.3.1 Analysis of Body of Evidence on Amino Quinolones in CoViD19 -- 5.4 Immune-Based Therapies in CoViD19 -- 5.4.1 Immunomodulatory Agents -- 5.4.2 Convalescent Plasma, and Antibody-Based Therapies -- 5.5 Potential Anti-inflammatory Mechanisms -- 5.5.1 NOD-Like Receptor Protein 3 (NLRP3)-Anti-inflammasomes -- 5.5.2 Neutrophil Extracellular Traps (NETs)-Anti NETosis Therapy -- 5.6 Anticoagulants -- 5.7 CoViD19 Vaccines -- 5.8 Summary -- References -- 6 An Introduction to the Pathogenetic Mechanisms of CoViD19 Complications -- 6.1 Introduction -- 6.2 Acute Pulmonary Injury -- 6.3 Sepsis and Multi-organ Failure -- 6.4 Renin Angiotensin System -- 6.5 Endothelin System -- 6.6 Immune-Inflammation -- 6.7 Summary -- References -- 7 Overview of Cytokines and CoViD19 -- 7.1 Introduction -- 7.2 Cytokines -- 7.2.1 Interferon -- 7.2.2 Interleukins -- 7.2.3 Chemokines -- 7.2.4 Colony Stimulating Factors -- 7.2.5 Tumor Necrosis Factor -- 7.3 Cytokine Storm in CoViD19 -- 7.3.1 Kinetics of the Cytokine Storm -- 7.3.2 The \"T\" Cell Response -- 7.3.3 Cytokines and Severity of CoViD19 -- 7.4 Cytokines in Cardiovascular and Metabolic Diseases -- 7.5 Summary -- References -- 8 The Renin-Angiotensin System in COVID19 -- 8.1 Introduction -- 8.2 The Renin Angiotensin System -- 8.2.1 ACE2 Synthesis and Distribution -- 8.2.2 ACE2 Expression -- 8.2.3 ACE2 Detection -- 8.3 The Dynamics of ACE2 Expression in CoViD19 -- 8.3.1 ACE2 Expression in Cardiovascular and Metabolic Conditions -- 8.3.2 The Dynamics of ACE2 Expression and Cardiovascular Risk in CoViD19 -- 8.3.3 Age and Gender Variations of ACE2 and CoViD19 -- 8.4 ACE2 is a Marker of Severity or a Compensatory Mechanism? -- 8.5 Summary -- References -- 9 Thrombosis in CoViD19."]
[{"$nulls":4},"9.1 Epidemiology -- 9.2 Mechanisms Promoting Thrombosis in CoViD19 -- 9.2.1 Renin Angiotensin System and Thrombosis -- 9.2.2 Endothelial Cell Damage and Thrombosis -- 9.2.3 Inflammation and Thrombosis -- 9.2.4 Microangiopathy and Thrombosis in CoViD19 -- 9.2.5 Platelets and Thrombosis in CoViD19 -- 9.2.6 D Dimers in CoViD19 -- 9.2.7 Hypoxia and Thrombosis -- 9.2.8 Ethnic Disparities, High-Risk Subgroups and Coagulation -- 9.3 Summary -- References -- 10 Pathogenesis of CoViD19-Miscellaneous Mechanisms -- 10.1 Introduction -- 10.2 Regulatory Peptide Systems in CoViD19 -- 10.2.1 Kallikrein-Kinin System -- 10.2.2 Endothelin System -- 10.2.3 Natriuretic Peptide System -- 10.3 Miscellaneous Mechanisms -- 10.3.1 Direct Viral Damage -- 10.3.2 Endoplasmic Reticulum Stress -- 10.3.3 Cell Death Modalities -- 10.3.4 Mitochondrial Dysfunction -- 10.4 Summary -- References -- 11 Myocardial Injury in CoViD19 -- 11.1 Introduction -- 11.2 Epidemiology of Myocardial Injury -- 11.3 Definition, Presentation, and Challenges of Myocardial Injury -- 11.4 Timing and Assessment of Myocardial Injury -- 11.5 Biomarkers of Myocardial Injury -- 11.6 Pathogenesis of the Myocardial Injury -- 11.7 Summary -- References -- 12 Heart Failure in CoViD19 -- 12.1 Epidemiology -- 12.2 Role of Comorbidities in Heart Failure with CoViD19 -- 12.3 Biomarkers of Heart Failure in CoViD19 -- 12.4 Pathogenetic Mechanisms of Heart Failure in CoViD19 -- 12.5 Summary -- References -- 13 Hypertension in CoViD19 -- 13.1 Epidemiology -- "]
[{"$nulls":4},"13.2 Complexities in Hypertension and CoViD19 -- 13.3 CoViD19 Susceptibility and Hypertension -- 13.4 Pathogenesis -- 13.5 Summary -- References -- 14 Cardiac Arrhythmias in CoViD19 -- 14.1 Epidemiology of Arrhythmias in CoViD19 -- 14.2 Pathogenesis of Arrhythmias in CoViD19 -- 14.3 Summary -- References -- 15 Acute Coronary Syndromes in CoViD19."]
[{"$nulls":4},"15.1 Epidemiology of Acute Coronary Syndromes in CoViD19 -- 15.2 Defining Acute Coronary Syndromes, Challenges in Presentation and Assessment -- 15.3 Pathogenesis of Acute Coronary Syndromes in CoViD19 -- 15.4 Summary -- References -- 16 Diabetes Mellitus and COVID19 -- 16.1 Epidemiology -- 16.2 Pathogenesis -- 16.3 Treatment Implications -- 16.4 Summary -- References -- 17 Obesity and COVID19 -- 17.1 Introduction -- 17.2 Pathogenetic Links - Obesity and CoViD19 -- 17.3 Summary -- References -- 18 The Older Age Adults and COVID19 -- 18.1 Epidemiology -- 18.1.1 Oder Age and CoViD19 Criticality -- 18.1.2 CoViD19 Fatality in Older Age Adults -- 18.1.3 Older Age and Cardiovascular Disease in CoViD19 -- 18.2 CoViD19 Biomarkers in Older Adults -- 18.3 Risk Mechanisms in Older Age and CoViD19 -- 18.3.1 Immune Dysfunction and Inflammation -- 18.3.2 ACE2 Mechanisms -- 18.3.3 Miscellaneous Age Related Mechanisms -- 18.4 Summary -- References -- 19 Gender Disparity in CoViD19 -- 19.1 Epidemiology -- 19.2 Discrepancies in the Epidemiological Data -- 19.3 Factors Associated with Gender Dichotomy -- 19.4 Gender Disparity in Immune Response -- 19.5 Gender Disparity in ACE2 Mechanisms -- 19.6 Gender Disparity in Cardiovascular Diseases -- 19.6.1 Cardiovascular Pathogenetic Features and Gender -- 19.7 Summary -- References -- 20 An Overview of Quality of Research in COVID19 -- 20.1 Introduction -- 20.2 Quality Issues in CoViD19 Research and Improvement Initiatives -- 20.3 Summary -- References -- Index."]